AlphaQuest LLC Purchases 15,769 Shares of Collegium Pharmaceutical, Inc. $COLL

AlphaQuest LLC boosted its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 170.8% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 25,003 shares of the specialty pharmaceutical company’s stock after purchasing an additional 15,769 shares during the period. AlphaQuest LLC’s holdings in Collegium Pharmaceutical were worth $875,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Collegium Pharmaceutical by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,046 shares of the specialty pharmaceutical company’s stock worth $569,000 after buying an additional 825 shares during the last quarter. Millennium Management LLC increased its position in shares of Collegium Pharmaceutical by 248.5% during the first quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock valued at $19,338,000 after acquiring an additional 461,914 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Collegium Pharmaceutical by 7.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,014 shares of the specialty pharmaceutical company’s stock worth $2,120,000 after acquiring an additional 4,625 shares during the last quarter. Jane Street Group LLC lifted its position in Collegium Pharmaceutical by 218.7% in the 1st quarter. Jane Street Group LLC now owns 131,520 shares of the specialty pharmaceutical company’s stock valued at $3,926,000 after acquiring an additional 90,255 shares in the last quarter. Finally, State of Alaska Department of Revenue boosted its stake in Collegium Pharmaceutical by 7.0% during the 2nd quarter. State of Alaska Department of Revenue now owns 19,127 shares of the specialty pharmaceutical company’s stock valued at $564,000 after purchasing an additional 1,257 shares during the last quarter.

Collegium Pharmaceutical Trading Up 2.6%

Collegium Pharmaceutical stock opened at $47.11 on Tuesday. Collegium Pharmaceutical, Inc. has a 52-week low of $23.23 and a 52-week high of $50.79. The company has a market cap of $1.49 billion, a P/E ratio of 29.26 and a beta of 0.64. The company has a quick ratio of 1.27, a current ratio of 1.36 and a debt-to-equity ratio of 2.71. The business has a 50-day simple moving average of $47.29 and a two-hundred day simple moving average of $40.31.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Thursday, November 6th. The specialty pharmaceutical company reported $2.25 earnings per share for the quarter, topping the consensus estimate of $1.89 by $0.36. The firm had revenue of $209.36 million for the quarter, compared to analysts’ expectations of $191.25 million. Collegium Pharmaceutical had a net margin of 7.72% and a return on equity of 102.03%. The business’s quarterly revenue was down 18.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.61 EPS. Analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Insiders Place Their Bets

In other news, EVP Scott Dreyer sold 17,600 shares of Collegium Pharmaceutical stock in a transaction on Monday, December 8th. The shares were sold at an average price of $48.17, for a total transaction of $847,792.00. Following the transaction, the executive vice president owned 103,613 shares in the company, valued at $4,991,038.21. This trade represents a 14.52% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Colleen Tupper sold 30,000 shares of the business’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $40.53, for a total transaction of $1,215,900.00. Following the sale, the chief financial officer directly owned 126,667 shares of the company’s stock, valued at approximately $5,133,813.51. The trade was a 19.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 51,250 shares of company stock worth $2,235,352. Company insiders own 2.51% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on COLL. Weiss Ratings restated a “buy (b-)” rating on shares of Collegium Pharmaceutical in a research note on Monday, December 29th. Needham & Company LLC lifted their price objective on Collegium Pharmaceutical from $48.00 to $56.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. Zacks Research cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Wall Street Zen upgraded shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Finally, HC Wainwright reissued a “buy” rating and set a $60.00 price objective (up from $46.00) on shares of Collegium Pharmaceutical in a report on Friday, January 9th. Five equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $52.80.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.